Boeke S, Hauth F, Fischer S G, Lautenbacher H, Bizu V, Zips D, Gani C
University Hospital Tübingen, Department of Radiation Oncology, Tübingen, Germany.
German Cancer Research Center (DKFZ) Heidelberg and German Consortium for Translational Cancer Research (DKTK), Partner Site Tübingen, Tübingen, Germany.
Tech Innov Patient Support Radiat Oncol. 2022 Apr 5;22:16-21. doi: 10.1016/j.tipsro.2022.03.004. eCollection 2022 Jun.
In radiotherapy the timely identification of patients needing intervention and supportive care due to side effects is an important task especially in the outpatient setting. Activity trackers as an increasingly used lifestyle device may enable physicians to monitor patient's physical activity (PA) and to intervene early during the course of radiotherapy.
The primary aim of this trial was to assess patient acceptance of PA monitoring in an outpatient setting and to correlate changes in PA with toxicity and changes in quality of life.
Patients undergoing radio(chemo-)therapy with a curative intent were eligible to participate in this prospective pilot phase II trial. Patients were instructed to wear a commercially available activity tracker during the course of radiotherapy and four weeks afterwards. Quality of life (QoL) and fatigue was scored using the Functional assessment of Chronic Illness Therapy questionnaire. A linear regression was performed to determine baseline activity and changes in step counts during radiotherapy.
We included 23 patients in this trial. Two withdrew consent before the start of treatment, two patients were excluded after prophylactic feeding tube placement and prolonged recovery. Compliance in the remaining 19 patients was high, with availability of step-counts on 92% of the days. Baseline step counts were 6274 for breast cancer patients and 3621 for patients with other entities. Decreasing activity during radiotherapy coincided with the development of side effects and declines in quality of life.
Activity trackers as tool to monitor PA during and after radiotherapy were accepted by a majority of the patients included in the current trial. Observed changes in PA correlated with patient reported side effects and QoL in some of the patients.
在放射治疗中，及时识别因副作用而需要干预和支持性护理的患者是一项重要任务，尤其是在门诊环境中。活动追踪器作为一种越来越常用的生活方式设备，可能使医生能够监测患者的身体活动（PA），并在放射治疗过程中尽早进行干预。
本试验的主要目的是评估门诊环境中患者对PA监测的接受程度，并将PA的变化与毒性和生活质量的变化相关联。
有治愈意图的接受放射（化学）治疗的患者有资格参加这项前瞻性II期试点试验。患者被指示在放射治疗期间及之后四周佩戴市售活动追踪器。使用慢性病治疗功能评估问卷对生活质量（QoL）和疲劳进行评分。进行线性回归以确定放疗期间的基线活动和步数变化。
我们在本试验中纳入了23名患者。两名患者在治疗开始前撤回同意，两名患者在预防性放置喂食管和恢复时间延长后被排除。其余19名患者的依从性很高，92%的日子有步数记录。乳腺癌患者的基线步数为6274步，其他实体患者为3621步。放疗期间活动减少与副作用的出现和生活质量下降同时发生。
活动追踪器作为放疗期间和放疗后监测PA的工具，被纳入本试验的大多数患者所接受。在一些患者中，观察到的PA变化与患者报告的副作用和QoL相关。
